Finance

Lists
EVMN:NYSE
Evommune Inc
5,77 USD
-1,87%
(-0,11) 1D
5,77 USD
0,00% (0,00)
After hours
Closed: 14-окт., 16:00:02 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for EVMN...
Open
5,79 USD
High
5,96 USD
Low
5,64 USD
Mkt. cap
209,41 млн
Avg. vol.
903,54 миң
Volume
2,00
52-wk high
33,20 USD
52-wk low
5,64 USD
EPS
-2,89 USD
Shares outstanding
36,29 млн
No. of employees
48
Open
5,79 USD
High
5,96 USD
Low
5,64 USD
Mkt. cap
209,41 млн
Avg. vol.
903,54 миң
Volume
2,00
52-wk high
33,20 USD
52-wk low
5,64 USD
EPS
-2,89 USD
Shares outstanding
36,29 млн
No. of employees
48
News stories
From web sources and news partners
About Evommune Inc
CEO-
Employees48
Founded2020
HeadquartersПало Альто, Калифорния, Америка Кошмо Штаттары
Sector-
Websiteevommune.com
Analyst ratings
Based on 13 analysts giving stock ratings to EVMN in the past 3 months
Strong buy
Buy
10
Hold
3
Sell
0
12-month forecast
Based on 13 Wall Street analysts offering 12 month price targets for EVMN in the last 3 months.
Highest
Current 5,77 USD
30,00 USD (+419,93%)
Average
22,40 USD (+288,21%)
Lowest
8,00 USD (+38,65%)
Analyst
Recommendation
Action
Price target
Projected
Date
Alice Nettleton
UBS
Hold
Initiated
8,00 USD
+38,6%
10/12/2026
Unknown Analyst
UBS
Hold
Initiated
8,00 USD
+38,6%
10/11/2026
Mitchell Kapoor
H.C. Wainwright
Hold
Reiterated
-
-
10/05/2026
Prakhar Agrawal
Cantor Fitzgerald
Buy
Maintained
-
-
09/17/2026
Kaveri Pohlman
Clear Street
Buy
Maintained
23,00 USD
+298,6%
09/09/2026
Alex Thompson CFA
Stifel Nicolaus
Buy
Maintained
30,00 USD
+419,9%
09/09/2026
Serge Belanger
Needham
Buy
Maintained
28,00 USD
+385,3%
09/09/2026
Thomas Smith
Leerink Partners
Buy
Reiterated
22,00 USD
+281,3%
09/10/2026
Martin Auster
Raymond James
Buy
Maintained
18,00 USD
+212%
09/09/2026
Kostas Biliouris
Oppenheimer
Buy
Reiterated
26,00 USD
+350,6%
09/09/2026
Brian Abrahams
RBC Capital
Buy
Maintained
21,00 USD
+264%
09/08/2026
Matt Phipps
William Blair
Hold
Maintained
-
-
09/09/2026
Gavin Clark-Gartner
Evercore ISI
Buy
Maintained
22,00 USD
+281,3%
08/10/2026
Judah Frommer
Morgan Stanley
Buy
Reiterated
26,00 USD
+350,6%
08/10/2026
Last report
2026-ж., 6-авг.
Fiscal period
Q2 2026
-0,89 USD / -0,67 USD
-32,84%miss
Revenue / Est. (USD)
- / 1,14 млн
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
10,00 млн
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
19,64 млн
20,40 млн
17,32 млн
26,41 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3,69 млн
9,31 млн
6,64 млн
8,48 млн
Operating expense
23,33 млн
29,72 млн
23,95 млн
34,90 млн
Total operating expenses
23,33 млн
29,72 млн
23,95 млн
34,90 млн
Operating income
-13,33 млн
-29,72 млн
-23,95 млн
-34,90 млн
Other non operating income
-9,00 миң
-
-4,00 миң
-2,00 миң
EBT including unusual items
-12,48 млн
-28,27 млн
-21,67 млн
-32,25 млн
EBT excluding unusual items
-12,48 млн
-28,27 млн
-21,67 млн
-32,25 млн
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-12,48 млн
-28,27 млн
-21,67 млн
-32,25 млн
Net profit margin
-124,75%
-
-
-
Earnings per share
-8,07
-1,43
-0,64
-0,89
Interest and investment income
862,00 миң
1,44 млн
2,28 млн
2,65 млн
Interest expense
-
-
-
-
Net interest expenses
862,00 миң
1,44 млн
2,28 млн
2,65 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
-13,02 млн
-29,39 млн
-23,60 млн
-34,34 млн
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google колдонмолору